Proactive Investors - Run By Investors For Investors

GW Pharma soars on news of positive trial for cannabis-based epilepsy drug

A second Phase 3 trial of the London-based company’s Epidiolex treatment for a severe form of childhood epilepsy produced positive results
stethoscope and marijuana leaf
The company focuses on developing novel therapeutics from its proprietary cannabinoid product platform

GW Pharmaceuticals PLC (NASDAQ:GWPH; ) shares climbed in premarket trade Monday, after the company said a second Phase 3 trial of its cannabis-based Epidiolex treatment for a severe form of childhood epilepsy produced positive results.

London-based GW Pharma’s lead product Epidolex, a cannabidiol oral medication for the treatment of seizures, takes aim at two types of childhood epilepsy, Dravet syndrome and Lennox-Gastaut syndrome.

GW Pharma said the trial met its primary endpoint of reducing convulsive seizures in patients suffering from Dravet syndrome. The endpoint was achieved at two dose levels, 10 mg a day and 20 mg a day, the company said in a statement.

READ: Leerink Partners starts coverage of GW Pharmaceuticals with Outperform rating and $185 price target

"The positive results from this latest Epidiolex clinical trial are very encouraging for those living with intractable seizures caused by LGS and Dravet syndrome, two extremely difficult treatment-resistant forms of epilepsy," said Philip M. Gattone, president and CEO of the Epilepsy Foundation.

The data represents the fourth positive Phase 3 pivotal trial for Epidiolex in treating Dravet syndrome and Lennox-Gastaut syndrome.

Epidiolex recently launched in the US and is now available by prescription. Leerink analyst Marc Goodman thinks Epidolex should be a blockbuster drug with sales of about $1.8 billion in 2026.

GW Pharma shares jumped 4.2% to $129.26 before the opening bell.

 

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

cannabis plan in sun
February 21 2019
The cannabis company will manufacture, infuse and package branded recreational and wellness products
cannabis tablet
February 28 2019
The company fills a niche in the medicinal cannabis market, as it continues to push forward its suite of precision oral dose products
Sydney Harbour Bridge
January 22 2019
A phase I study in Australia is evaluating a cannabis spray therapeutic in cancer patients.
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use